Aim: To determine quality of life, effectiveness and safety of oral netupitant-palonosetron (NEPA)–based antiemetic prophylaxis in the real-world setting. Materials & methods: Prospective, noninterventional study in adults receiving highly or moderately emetogenic chemotherapy and NEPA for three cycles. NEPA was administered per summary of product characteristics. Results: A total of 2429 patients enrolled, 2173 were evaluable. ‘No impact on daily life’ due to vomiting was reported by 84%/82% of patients in the highly emetogenic chemotherapy/moderately emetogenic chemotherapy groups in cycle 1, with rates of 54%/59% for nausea. Overall, complete response rate was 89%/87%/83% in the acute/delayed/overall phases. NEPA was well tolerated. Conclusion: NEPA had beneficial effects on the quality of life of a heterogeneous group of cancer patients and was safe and effective in the real-world setting.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 374(14), 1356–1367 (2016). •• Comprehensive review of chemotherapy-induced nausea and vomiting.
Medline CASGoogle Scholar
2. Ballatori E, Roila F, Ruggeri B et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support. Care Cancer 15(2), 179–185 (2007).
MedlineGoogle Scholar
3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. 24(27), 4472–4478 (2006).
Medline CASGoogle Scholar
4. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer 15(5), 497–503 (2007).
MedlineGoogle Scholar
5. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support. Care Cancer 12(10), 708–715 (2004).
MedlineGoogle Scholar
6. Basch E, Deal AM, Dueck AC et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2), 197–198 (2017).
MedlineGoogle Scholar
7. Bošnjak SM, Gralla RJ, Schwartzberg L. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK₁) receptor antagonists. Support. Care Cancer 25(5), 1661–1671 (2017).
MedlineGoogle Scholar
8. Aapro M, Molassiotis A, Dicato M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann. Oncol. 23(8), 1986–1992 (2012).
Medline CASGoogle Scholar
9. Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support. Care Cancer 20(1), 141–147 (2012).
MedlineGoogle Scholar
10. Gilmore JW, Peacock NW, Gu A et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J. Oncol. Pract. 10(1), 68–74 (2014).
MedlineGoogle Scholar
11. Deutsche Krebsgesellschaft. [Guideline program oncology. Supportive therapy for oncological patients] (2019). www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.2.pdf
Google Scholar
12. Roila F, Molassiotis A, Herrstedt J et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 27(Suppl. 5), v119–v133 (2016).
Medline CASGoogle Scholar
13. Multinational Association of Supportive Care in Cancer. MASCC/ESMO Antiemetic Guidelines (2019). www.mascc.org/antiemetic-guidelines • Most recent Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology antiemetic guidelines.
Google Scholar
14. Hesketh PJ, Kris MG, Basch E et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J. Clin. Oncol. 35(28), 3240–3261 (2017). • Most recent American Society of Clinical Oncology antiemetic guidelines.
Medline CASGoogle Scholar
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®). Antiemesis. Version 1.2020 (2020). www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf • Most recent National Comprehensive Cancer Network antiemetic guidelines.
Google Scholar
16. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15(1), 103–109 (1997).
Medline CASGoogle Scholar
17. Grunberg SM, Warr D, Gralla RJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–state of the art. Support. Care Cancer 19(Suppl. 1), S43–S47 (2011).
MedlineGoogle Scholar
18. Jordan K, Chan A, Gralla RJ et al. 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support. Care Cancer 25(1), 271–275 (2017).
MedlineGoogle Scholar
19. Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep. 1(4), e1127 (2018).
Google Scholar
20. Aapro MS, Scotté F, Escobar Y et al. Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data. Ann. Oncol. 29(Suppl.8), viii603, abstract 1681O (2018).
Google Scholar
21. Jordan K, Lux MP, Franceschetti A et al. Analysis of real-world prescribing patterns for the management of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence. Presented at: Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DGHO) 2019 Congress. Berlin, Germany (2019).
Google Scholar
22. Dranitsaris G, Molassiotis A, Clemons M et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann. Oncol. 28(6), 1260–1266 (2017).
Medline CASGoogle Scholar
23. Clark-Snow RA, Affronti ML, Rittenberg CN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support. Care Cancer 26(2), 557–564 (2018).
MedlineGoogle Scholar
24. Dielenseger P, Börjeson S, Vidall C, Young A, Jahn P. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support. Care Cancer 27(11), 4099–4106 (2019).
MedlineGoogle Scholar
25. Vidall C, Fernández-Ortega P, Cortinovis D, Jahn P, Amiani B, Scotté F. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Support. Care Cancer 23(11), 3297–3305 (2015).
MedlineGoogle Scholar
26. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur. J. Pharmacol. 684(1–3), 1–7 (2012).
Medline CASGoogle Scholar
27. Hesketh PJ, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann. Oncol. 25(7), 1340–1346 (2014). • Pivotal study to determine the dose of netupitant to combine with palonosetron 0.50 mg for further clinical evaluation of netupitant-palonosetron (NEPA).
Medline CASGoogle Scholar
28. Aapro M, Rugo H, Rossi G et al. A randomized Phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 25(7), 1328–1333 (2014). • Pivotal study that evaluates the efficacy of NEPA in patients receiving anthracycline-cyclophosphamide.
Medline CASGoogle Scholar
29. Gralla RJ, Bosnjak SM, Hontsa A et al. A Phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol. 25(7), 1333–1339 (2014). • Pivotal study that evaluates the safety and efficacy of NEPA over multiple cycles of highly and moderately emetogenic chemotherapy.
Medline CASGoogle Scholar
30. Zhang L, Lu S, Feng J et al. A randomized Phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann. Oncol. 29(2), 452–458 (2018). • Phase III study comparing the antiemetic efficacy of NEPA and aprepitant regimens.
Medline CASGoogle Scholar
31. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21(22), 4112–4119 (2003).
Medline CASGoogle Scholar
32. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23(12), 2822–2830 (2005).
Medline CASGoogle Scholar
33. Rapoport BL, Chasen MR, Gridelli C et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, Phase III trials. Lancet Oncol. 16(9), 1079–1089 (2015).
Medline CASGoogle Scholar
34. Schwartzberg LS, Modiano MR, Rapoport BL et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, Phase III trial. Lancet Oncol. 16(9), 1071–1078 (2015).
Medline CASGoogle Scholar
35. Aapro M, Karthaus M, Schwartzberg L et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, Phase III trial versus oral palonosetron. Support. Care Cancer 25(4), 1127–1135 (2017).
MedlineGoogle Scholar
36. Schwartzberg L, Roeland E, Andric Z et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann. Oncol. 29(7), 1535–1540 (2018).
Medline CASGoogle Scholar
37. Schwartzberg L, Navari R, Clark-Snow R et al. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline/cyclophosphamide (AC) chemotherapy. Oncologist 25, e589–e597 (2020).
Medline CASGoogle Scholar
38. Akynzeo^® (netupitant and palonosetron) capsules; Akynzeo^® (fosnetupitant and palonosetron) for injection, prescribing information. Dublin, Ireland (2018). Helsinn Birex Pharmaceuticals Ltd, Dublin, Ireland
Google Scholar
39. EMA. Summary of opinion (post authorization). Akynzeo (fosnetupitant/palonosetron). EMA/CHMP/670824/2019. www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-akynzeo_en.pdf
Google Scholar
40. Jordan K, Aapro M, Kaasa S et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann. Oncol. 29(1), 36–43 (2018).
Medline CASGoogle Scholar
41. Basch E, Deal AM, Kris MG et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J. Clin. Oncol. 34(6), 557–565 (2016).
Medline CASGoogle Scholar
42. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support. Care Cancer 11(8), 522–527 (2003).
Medline CASGoogle Scholar
43. Ganz PA, Gotay CC. Use of patient-reported outcomes in Phase III cancer treatment trials: lessons learned and future directions. J. Clin. Oncol. 25(32), 5063–5069 (2007).
MedlineGoogle Scholar
44. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat. Methods Med. Res. 23(5), 440–459 (2014).
MedlineGoogle Scholar
45. Molassiotis A, Lee PH, Burke TA et al. Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study. J. Pain Symptom Manage. 51(6), 987–993 (2016).
MedlineGoogle Scholar
46. Schwartzberg LS, McLaughlin T, Geller RB, Gabrail NY, Marks SM. Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. J. Comp. Eff. Res. 7(12), 1161–1170 (2018).
MedlineGoogle Scholar
47. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized Phase III trial. J. Support. Oncol. 9(5), 188–195 (2011).
Medline CASGoogle Scholar
48. Di Maio M, Gallo C, Leighl NB et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J. Clin. Oncol. 33(8), 910–915 (2015).
MedlineGoogle Scholar
49. Childs DS, Looker S, Le-Rademacher J, Ridgeway JL, Breitkopf CR, Jatoi A. What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. Support. Care Cancer 27(1), 249–255 (2019).
MedlineGoogle Scholar
50. Escobar Y, Cajaraville G, Virizuela JA et al. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support. Care Cancer 23(9), 2833–2840 (2015).
MedlineGoogle Scholar
51. Majem M, Moreno ME, Calvo N et al. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support. Care Cancer 19(12), 1983–1990 (2011).
MedlineGoogle Scholar

Vol. 16, No. 14

Supplemental Materials

Metrics

Downloaded 4,253 times

History

Received 3 March 2020

Accepted 27 March 2020

Published online 16 April 2020

Published in print May 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0187

Acknowledgments

The authors thank the patients, investigators and the study teams.

Financial & competing interests disclosure

The study described within this paper was sponsored by RIEMSER Pharma GmbH, Berlin, Germany. Helsinn Healthcare SA and RIEMSER Pharma GmbH also participated in the writing, review, and approval of the manuscript. M Karthaus is on the ad board and has received travel grants from Helsinn and RIEMSER. E Flahaut is a RIEMSER employee. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editorial support and medical writing assistance were provided by Iratxe Abarrategui, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, funded by Helsinn Healthcare SA, Lugano, Switzerland. The authors are fully responsible for all content and editorial decisions for this manuscript.

Clinical trial identification

DRKS00009316.

PDF download